- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07791212
Dissecting Immunological and Autoimmune Mechanisms of Neuropsychiatric Diseases (DIAMOND)
The goal of this observational cohort study is to investigate the role of immune system in neuropsychiatric symptoms (NPS) and to identify immunological biomarkers that may improve the diagnosis, prognosis, and future treatment of immune-related neuropsychiatric disorders in individuals aged 16-100 years with suspected immune-mediated neuropsychiatric symptoms and matched control participants without neuropsychiatric symptoms.
The main questions it aims to answer are what immunological mechanisms are associated with neuropsychiatric symptoms across a range of neurological, psychiatric, autoimmune, infectious, and inflammatory conditions. Also, if immunological biomarkers can be identified that may support the diagnosis, prognosis, and future treatment of neuropsychiatric disorders in which the immune system may play a role.
Participants will provide a blood sample for immunological analysis and may optionally provide a cerebrospinal fluid (CSF) sample if a suitable previously collected sample is not available. Researchers may also analyse existing clinical and biological samples where available. Participants will provide demographic and clinical information, allow access to relevant medical record data, and may optionally provide additional blood samples, up to four times within one year, for further biomarker and immunological analyses.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studieorter
-
-
-
London, Storbritannien, SE5 9RS
- King's College Hospital
-
London, Storbritannien, SE5 8AB
- South London and Maudsley NHS Foundation Trust
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Testmetod
Studera befolkning
Beskrivning
INCLUSION CRITERIA
Participants with Neuropsychiatric symptoms
- Age 16-100.
- Current or previous neuropsychiatric symptoms within the last year.
- Suspicion of immunological contribution to the aetiology of their neuropsychiatric symptoms.
Control Participants
- Age 16-100.
- No current or previous self-report of neuropsychiatric symptoms within the last year.
Optional Lumbar Puncture only:
- Documented full blood count within the last 3 months with no clinically significant abnormalities.
EXCLUSION CRITERIA
All Participants:
- Unacceptable risk of harm to participant or study staff due to risk of behavioural disturbance.
- Inability to have blood tests.
Optional Lumbar Puncture only:
- Significant lower spinal deformity (such as spina bifida), injury, or disease (such as stenosis) or previous lower spinal surgery.
- Antiplatelet or anticoagulant therapy within the 14 days prior to Lumbar Puncture procedure.
- Known or suspected clotting disorder.
- Clinically significant abnormality in full blood count.
- Known or suspected raised intracranial pressure, assessed by study clinician.
- Known or suspected allergy to local anaesthetic agent or an ingredient of the anaesthetic solution.
- History of chronic or recurrent headaches, in the opinion of the investigator.
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
|---|
|
Kontrolldeltagare
|
|
Participants with neuropsychiatric symptoms
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Neuronal Autoantibodies
Tidsram: From enrolment through to 1 year of follow-up.
|
Differences in the prevalence, subtype, and functional characteristics of neuronal autoantibodies in serum and cerebrospinal fluid between participants with neuropsychiatric symptoms (NPS) and matched control participants.
|
From enrolment through to 1 year of follow-up.
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Neurologiska manifestationer
- Sjukdomar i nervsystemet
- Schizofrenispektrum och andra psykotiska störningar
- Mentala störningar
- Patologiska processer
- Autoimmuna sjukdomar
- Immunsystemets sjukdomar
- Beteendesymtom
- Neurobehavioral manifestationer
- Patologiska tillstånd, tecken och symtom
- Beteende
- Tecken och symtom
- Psykotiska störningar
- Inflammation
- Catatonia
- Autoimmuna sjukdomar i nervsystemet
Andra studie-ID-nummer
- 354922
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .